The veteran crew at Medicxi is back with a new $400M fund and an upbeat assessment of what’s coming

Bioregnum Opinion Column by John Carroll

No two biotech VC groups are exactly the same.

Each has its own specialty, each has its ideas about assets and platforms. And you can certainly place the experienced crew at Medicxi in the asset wing — with a…
Click here to view original post